The European Medicines Agency recommends emergency use of Merck’s Covid-19 drug monelavir, although the drug has not yet been approved.
In a statement on November 19, the European Medicines Agency (EMA) stated that molnupiravir can be used to treat nCoV-infected adults who do not yet need supplemental oxygen and are at increased risk of deterioration.
According to the agency, the drug should be taken as soon as possible after the virus infection is detected, and twice a day for five days within five days of the onset of symptoms.
“This recommendation is intended to help governments that may make decisions about the viability of monelavir before it is approved for marketing, such as in emergency situations, where the Covid infection rate and death rate are high.” -19 throughout Europe is increasing the Union (EU)”, EMA explained.
The most common adverse events observed during treatment and within 14 days after the last dose of monoprevir were diarrhea, nausea, dizziness, and headache, all of which were mild to moderate. The EMA advises against taking the drug for pregnant and breastfeeding women, adding that it is undergoing a full review.
Due to the re-emergence of Covid-19, Europe is once again in trouble and is assessed by the World Health Organization (WHO) as the current global epicenter. Lothar Weiler, head of the German disease control and prevention agency, said that the entire country has become a major outbreak.
Earlier this month, the United Kingdom became the first country in the world to approve Monopiravir. Merck’s drugs work by reducing the virus’ ability to reproduce. Data from later studies show that for adult Covid-19 patients with mild to moderate infections, molnupiravir reduces the risk of hospitalization and death by 50%. Merck also applied to the U.S. Food and Drug Administration (FDA) for a license for monelavir.
luster (follow Associated Press)